<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997009</url>
  </required_header>
  <id_info>
    <org_study_id>MITO CERV 2</org_study_id>
    <secondary_id>2009-010099-74</secondary_id>
    <nct_id>NCT00997009</nct_id>
  </id_info>
  <brief_title>Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer</brief_title>
  <acronym>MITO CERV 2</acronym>
  <official_title>Randomized Phase II Study of Carboplatin and Paclitaxel +/- Cetuximab, in Advanced and/or Recurrent Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the activity of a combination of cetuximab (weekly) with
      carboplatin + paclitaxel (every three weeks) comparing it to chemotherapy alone in terms of
      event-free survival (EFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The poor long-term results in the standard treatment of chemotherapy for cervical cancer make
      research into new, more beneficial treatment strategies necessary. Cetuximab is a new type of
      drug that blocks the epidermal growth factor receptor (anti-EFGR), and has shown significant
      activity in other cancers (colon, head and neck) where expression of EGFR is high. Cervical
      cancer cells express EGFR in a very high proportion of cases, especially in recurrent or
      resistant disease. This study evaluates the activity of the addition of cetuximab to full
      doses of carboplatin and paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event free survival</measure>
    <time_frame>after 3 and 6 cycles of treatment, and every 3 months thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>after each treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin toxicity and correlation with cetuximab activity</measure>
    <time_frame>after 3 and 6 cycles of therapy, and every 3 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGFR/KRAS expression and correlation with cetuximab activity</measure>
    <time_frame>at 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy plus cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>175 mg/m2 IV day 1, every 21 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 5 IV day 1 every 21 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced and/or metastatic cervical cancer patients untreated or having failed only
             one previous chemotherapy (with at least 6 months of progression free interval, with
             or without concomitant or sequential radiotherapy).

          -  At baseline, presence of at least one measurable target lesion (a lesion that can be
             accurately measured in at least one dimension i.e. longest diameter at least 20 mm
             with conventional CT scan or at least 10 mm with spiral CT scan according to RECIST
             Criteria).

          -  Not amenable to surgery and/or radiotherapy.

          -  PS 0-1 according to ECOG.

          -  Age &gt;18.

          -  Life expectancy of at least 3 months.

          -  Adequate organ functions

               -  Hematopoietic: Leukocytes &gt; 3,000/mm3; Absolute neutrophil count &gt; or =
                  1,500/mm3; Platelets count &gt; or = 100,000/mm3; Hemoglobin &gt; or = 9 g/dL

               -  Hepatic: AST and ALT &lt; or = 3 times upper limit of normal (ULN)*; Alkaline
                  phosphatase &lt; or = 3 times ULN*; Bilirubin &lt; or = 1.5 times ULN

                  *: &lt; or = 5 times ULN if liver metastases are present

               -  Renal: Creatinine clearance &gt; or = 45 mL/min

          -  No other invasive malignancy within the past 5 years except non-melanoma skin cancer.

          -  All radiology studies must be performed within 28 days prior to randomization.

          -  Absence of any psychological, familial, sociological or geographical conditions
             potentially hampering compliance with the study protocol and follow-up schedule.

          -  Written informed consent.

        Exclusion Criteria:

          -  Pregnant (potentially fertile patients must use contraceptive measures to avoid
             pregnancy during and for at least 3 months after study participation and must have a
             negative serum pregnancy test at baseline).

          -  Patients should not be breast-feeding during treatment and for 2 months following the
             end of treatment.

          -  More than one previous chemotherapy line.

          -  Active infection requiring antibiotics.

          -  Symptomatic peripheral neuropathy &gt;grade 2 according to the CTCAE.

          -  Congestive heart failure or angina pectoris even if it is medically controlled.
             Previous history of myocardial infarction within 1 year from study entry, uncontrolled
             high risk hypertension or arrhythmia.

          -  Known hypersensitivity to the study drugs or to drugs with similar chemical
             structures.

          -  Concurrent treatment with other experimental drugs.

          -  Participation in another clinical trial with any investigational drug within 30 days
             prior to study screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Morabito, M.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico A. Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Unversitaria Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Università di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Silvestrini</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. di Udine S. Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

